Three stocks fell as much as 10% on Thursday. The growth investor was buying.
Gene therapy and gene editing are marvels of modern biotechnology, providing revolutionary techniques for fixing genetic abnormalities. Gene therapy introduces functional genetic material to ...
Forget Vertex Pharmaceuticals -- CRISPR Therapeutics is a better buy right now.
On the buying side, ARK made a substantial acquisition of 338,299 shares of Figma Inc (FIG), with 289,241 shares through its ARKK ETF and 49,058 shares through its ARKW ETF, totaling $8,748,412. This ...
In May 2025, the world celebrated the success of KJ, an infant who was treated with the world’s first personalized CRISPR gene editing therapy. KJ was born with severe carbamoyl phosphate synthetase 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results